Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.


Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by Reaxense.


The library includes a list of the most effective modulators, each annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Furthermore, each compound is shown with its optimal docking poses, affinity scores, and activity scores, offering a detailed summary.


Our high-tech, dedicated method is applied to construct targeted libraries for receptors.


 

Fig. 1. The screening workflow of Receptor.AI

The method involves detailed molecular simulations of the receptor in its native membrane environment, with ensemble virtual screening focusing on its conformational mobility. When dealing with dimeric or oligomeric receptors, the whole functional complex is modelled, and the tentative binding pockets on and between the subunits are established to address all possible mechanisms of action.


Several key aspects differentiate our library:


  • Receptor.AI compiles an all-encompassing dataset on the target protein, including historical experiments, literature data, known ligands, and structural insights, maximising the chances of prioritising the most pertinent compounds.

  • The platform employs state-of-the-art molecular simulations to identify potential binding sites, ensuring the focused library is primed for discovering allosteric inhibitors and binders of concealed pockets.

  • Over 50 customisable AI models, thoroughly evaluated in various drug discovery endeavours and research projects, make Receptor.AI both efficient and accurate. This technology is integral to the development of our focused libraries.

  • In addition to generating focused libraries, Receptor.AI offers a full range of services and solutions for every step of preclinical drug discovery, with a pricing model based on success, thereby reducing risk and promoting joint project success.


PARTNER
Receptor.AI
 
UPACC
P32246

UPID:
CCR1_HUMAN

ALTERNATIVE NAMES:
HM145; LD78 receptor; Macrophage inflammatory protein 1-alpha receptor; RANTES-R

ALTERNATIVE UPACC:
P32246; Q86VA9

BACKGROUND:
The C-C chemokine receptor type 1 (CCR1) serves as a critical receptor for C-C type chemokines, engaging with ligands such as MIP-1-alpha and RANTES to modulate intracellular calcium levels. This receptor is integral in the regulation of immune responses and stem cell proliferation, showcasing its versatility in cellular signaling pathways.

THERAPEUTIC SIGNIFICANCE:
Exploring the functionalities of C-C chemokine receptor type 1 unveils promising avenues for therapeutic intervention. Its key role in immune modulation and cell proliferation positions it as an attractive target for developing novel treatments in immunotherapy and tissue regeneration.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.